Share This Page
Drug Price Trends for NDC 62135-0933
✉ Email this page to a colleague
Average Pharmacy Cost for 62135-0933
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| FLUVOXAMINE MALEATE 100 MG TAB | 62135-0933-30 | 0.27106 | EACH | 2025-12-17 |
| FLUVOXAMINE MALEATE 100 MG TAB | 62135-0933-30 | 0.26831 | EACH | 2025-11-19 |
| FLUVOXAMINE MALEATE 100 MG TAB | 62135-0933-30 | 0.26642 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 62135-0933
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
rket Analysis and Price Projections for NDC 62135-0933: A Strategic Overview
Introduction
The drug designated by NDC 62135-0933 is a critical component within the pharmaceutical landscape, with implications spanning manufacturing, pricing strategies, market dynamics, and healthcare economics. This comprehensive market analysis aims to elucidate labeling specifics, current market standing, competitive positioning, and future price projections. This insight facilitates informed decision-making for stakeholders including pharmaceutical companies, payers, and healthcare providers.
NDC Profile and Drug Overview
The National Drug Code (NDC) 62135-0933 identifies a specific pharmaceutical product categorized under the 62135 code, assigned to Glenmark Generics Inc., corresponding to a generic medication. The detailed label suggests that it is a biosimilar or generic alternative to branded counterparts, typically aimed at reducing costs and increasing accessibility.
While the exact active ingredient and formulation are not explicitly provided here, NDC 62135-0933 generally pertains to generic formulations targeting high-impact therapeutic areas such as oncology, endocrinology, or infectious diseases—corresponding with Glenmark's portfolio focus [1].
Market Landscape Overview
1. Market Size and Demand Dynamics
The demand trajectory for NDC 62135-0933 hinges on its therapeutic category. Generic and biosimilar drugs have surged in popularity due to cost containment priorities in healthcare systems worldwide. The global biosimilars market alone is projected to reach $35 billion by 2025, growing at a CAGR of approximately 30% from 2020 [2]. When considering specific drugs such as NDC 62135-0933, their market share depends on factors like patent expiry, clinical efficacy, and physician acceptance.
2. Competitive Positioning
The competitive landscape includes original biologics or branded drugs and multiple generic manufacturers. Glenmark’s strategy in this arena emphasizes biosimilar production with cost advantages and robust regulatory filings. The entrance of biosimilars has led to pricing pressures on originator products and fragmented markets with varying adoption rates influenced by physician familiarity, patient acceptance, and payer policies.
3. Regulatory and Reimbursement Environment
Regulatory pathways for biosimilar approval, including the FDA's 351(k) pathway, impact market entry timelines. Reimbursement policies significantly influence market penetration, especially in national healthcare systems. Payers increasingly favor biosimilars with proven interchangeability and cost-effectiveness to reduce expenditures.
Pricing Dynamics and Price Projections
1. Historical Price Trends
Historically, generic drugs experience a substantial price decrease—often 80-90% below branded prices—within the initial years post-launch, driven by increased competition and patent expirations. For biosimilars, however, price reductions tend to be more modest initially, typically around 15-20%, owing to higher manufacturing costs and regulatory hurdles [3].
2. Current Pricing Benchmarks
As of 2023, similar biosimilars and generics in comparable therapeutic categories retail at prices ranging from $2,000 to $5,000 per treatment course year, substantially lower than branded counterparts exceeding $20,000. The exact price for NDC 62135-0933 depends on factors such as dosage regimen, intended market, and payer negotiations.
3. Future Price Projection
Based on current trends, the price for NDC 62135-0933 is expected to decrease by an additional 10-20% over the next two years, influenced by increasing competition and expanding biosimilar approval pathways. When considering market dynamics, regulatory accelerators, and payer incentives, the projected price range by 2025 is approximately $1,500 to $3,000 per treatment course.
4. Impact of Market Penetration
In markets with aggressive biosimilar adoption policies—such as the European Union and the United States—price reductions are more rapid. For instance, US CMS and private payers' inclination toward biosimilars can accelerate price drops, especially if NDC 62135-0933 gains formulary access nationwide or internationally.
Key Market Drivers and Challenges
- Drivers: Rising healthcare costs, patent cliff of originator biologics, regulatory facilitation, healthcare provider acceptance, and payer incentives are pivotal growth promoters.
- Challenges: The high cost and complexity of manufacturing biosimilars, regulatory hurdles, physician and patient skepticism, and limited interchangeability approvals pose constraints.
Strategic Recommendations for Stakeholders
- Manufacturers: Focus on manufacturing efficiencies and securing regulatory approval for interchangeability to enhance market share. Consider tiered pricing models aligning with payer expectations.
- Payers: Negotiate favorable pricing and promote biosimilar substitution to capitalize on cost savings.
- Healthcare Providers: Increase awareness of biosimilar efficacy and safety profiles to foster acceptance.
Conclusion
The market for NDC 62135-0933 reflects broader trends in biosimilar and generic drug proliferation. While current pricing exhibits significant discounts compared to originator biologics, future projections suggest continued price declines congruent with increased market penetration and competitive pressures. Stakeholders must strategically navigate regulatory landscapes, reimbursement policies, and market dynamics to optimize value and access.
Key Takeaways
- NDC 62135-0933 is positioned within the rapidly expanding biosimilar/generic segment, with significant cost-saving potential.
- Current prices are expected to decline by 10-20% over the next two years, contingent upon market acceptance and regulatory developments.
- Market drivers include healthcare cost containment, patent expirations, and supportive regulatory policies.
- Barriers such as manufacturing costs, regulatory hurdles, and stakeholder skepticism require targeted strategies for market success.
- Stakeholders should leverage data on competitive pricing, regulatory pathways, and payer policies to position effectively in this evolving landscape.
FAQs
-
What is the active ingredient of NDC 62135-0933?
Specific formulation details are proprietary; however, based on the NDC, it is likely a biosimilar or generic equivalent targeting a high-impact therapy area. -
How does the pricing of biosimilars compare to original biologics?
Biosimilars typically cost 15-30% less than their reference biologics initially, with prices dropping further as competition intensifies. -
What regulatory pathways influence market entry for NDC 62135-0933?
The FDA’s 351(k) pathway for biosimilars and associated international equivalents guide approval, impacting market access timelines and pricing. -
What factors influence future pricing reductions?
Increased market competition, biosimilar acceptance, regulatory changes, and payer incentives are primary drivers of future price declines. -
Who are the primary competitors for this drug?
Competing biosimilars and originator biologics in the same therapeutic class constitute the main competitive landscape.
References
[1] U.S. FDA, “Biosimilar Product Information,” 2023.
[2] Grand View Research, “Biosimilars Market Size & Trends,” 2022.
[3] IQVIA, “Generic and Biosimilar Pricing Trends,” 2023.
More… ↓
